Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MML is on the SAB of Bayer HealthCare Pharmaceuticals Inc. DD receives honoraria/advisory boards for Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd , mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, i3 Health, MonteRosa, holds equity from Treeline Bio, receives royalties from Wolters Kluwer, and CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd. TWL owns stock in Advanced Microbubbles, has consulted for AI Therapeutics, Bayer, Cellectis, Deciphera, GentiBio, Jazz Pharmaceuticals, Jumo Health, Massive Bio, Menarini, Novartis, Pyramid Biosciences, and y-mAbs Therapeutics and has received research funding via his institution from Abbvie, Amgen, Atara Biotherapeutics, Bayer, BMS, Lilly, Epizyme, Foundation Medicine, GSK, Janssen, Jubilant Pharmaceuticals, Merck, Novartis, Novella Clinical, Pfizer, Servier, and Turning Point Therapeutics.